News about "Takeda "

Denali Regains Full Rights to DNL593 After Takeda Ends Collaboration

The biotech firm will independently advance its investigational therapy for frontotemporal dementia, with Phase I/II trial results expected by 2026.

Takeda | 08/04/2026 | By News Bureau |  102

Takeda's Zasocitinib Shows Strong Skin Clearance in Psoriasis Study

Takeda reports Phase 3 data showing zasocitinib delivers rapid, durable skin clearance in psoriasis, with ~70 percent achieving sPGA 0/1 and early PASI 75 response, with a consistent safety profile.

Takeda | 30/03/2026 | By News Bureau |  175

Takeda's Oveporexton NDA Accepted by US FDA with Priority Review for Narcolepsy Type 1

FDA grants Priority Review to Takeda’s investigational orexin receptor agonist oveporexton (TAK-861) for narcolepsy type 1, with a PDUFA decision expected in Q3 this year.

Takeda | 11/02/2026 | By News Bureau |  147

Takeda Becomes a BaseLaunch Partner

BaseLaunch has added Takeda as a new pharmaceutical partner to its biotech venture incubator, expanding its network of global pharma backers supporting and funding early-stage drug development startups.

Takeda | 19/12/2025 | By News Bureau |  122

Innovent Biologics and Takeda Finalise Global Collaboration for Next-Generation IO and ADC Therapies

As part of the agreement, Takeda will pay Innovent an upfront payment of USD1.2 billion, including a USD100 million equity investment at HKD112.56 per share.

Takeda | 05/12/2025 | By Dineshwori |  132

Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata

Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.

Takeda | 01/09/2025 | By Dineshwori |  220

BridGene Biosciences Signs Deal with Takeda to Discover Small Molecule Drugs

Under the terms of the collaboration, BridGene will use its chemoproteomics platform, IMTAC™, to discover novel small molecule drug candidates against challenging targets in immunology and neurology.

Takeda | 26/02/2025 | By Aishwarya |  443

Halozyme Announces Takeda Gets Approval for HYQVIA with ENHANZE in Japan

HYQVIA® is the first plasma-derived therapy for subcutaneous injection in Japan that consists of a combination of one vial of Immunoglobulin 10 percent and one vial of Recombinant Human Hyaluronidase PH20 (rHuPH20), which is Halozyme's ENHANZE drug delivery technology.

Takeda | 31/12/2024 | By Aishwarya |  398

Lupin and Takeda to Commercialize Vonoprazan in India

Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India.

Takeda | 19/09/2024 | By Aishwarya |  837

Mankind Pharma Signs License Deal with Takeda to Commercialise Acidity Drug in India

Mankind Pharma has signed a non-exclusive patent licence agreement with Takeda Pharmaceuticals for commercialising acidity drug Vonoprazan in the Indian market.

Takeda | 22/07/2024 | By Aishwarya |  1060